The functional impact of adding salmeterol and tiotropium in patients with stable COPD

被引:70
作者
Cazzola, M
Centanni, S
Santus, P
Verga, M
Mondoni, M
di Marco, F
Matera, MG
机构
[1] Osped Antonio Cardarelli, Dept Resp Med, Unit Pneumol & Allergol, I-80121 Naples, Italy
[2] Univ Milan, San Paolo Hos, Resp Med Unit, Milan, Italy
[3] Univ Naples 2, Pharmacol Unit, Dept Expt Med, Naples, Italy
关键词
salmeterol; tiotropium; combination therapy; COPD;
D O I
10.1016/j.rmed.2004.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this double-blind, double-dummy, crossover, randomised, pilot study was to explore the acute effects of adding salmeterol and tiotropium in patients with stable COPD. A total of 20 outpatients with stable COPD were enrolled. Single doses of 18-mug tiotropium, 50-mug salmeterol, and 18-mug tiotropium + 50-mug salmeterol were given. Serial measurements of forced expiratory volume in 1 s (FEV1) were performed over 24h. The mean maximum increases in FEV1 from pre-dosing value on each of the dosing days were 0.165l (95% CI: 0.098-0.232) for tiotropium, 0.241l(95% CI: 0.151-0.332) for salmeterol, and 0.290l(95% CI: 0.228-0.353) for the combination and occurred 4 h after inhalation of tiotropium or salmeterol and 3 h after the combination. At 12h, the mean increases in FEV1 from pre-dosing value were 0.071l(95% CI: 0.001-0.141; P = 0.047) for tiotropium, 0.069l(95% CI: 0.0180-0.120; P = 0.010) for salmeterol, and 0.108l(95% CI: 0.047-0.170; P = 0.001) for the tiotropium + salmeterol combination. Only the difference between salmeterol and tiotropium + salmeterol was statistically significant (P = 0.009). At 24 h, the mean FEV1 value was still higher than the mean pre-dosing value for tiotropium (0.042l; 95% CI: -0.012-0.097; P = 0.119) and the tiotropium + satmeterol combination (0.051l; 95% CI: 0.015-0.087; P = 0.007), but not for salmeterol alone (-0.013l; 95% CI: -0.041-0.014; P = 0.324). The FEV1 area under the curve (AUCs(0-12h)) were 1.657l(95% CI: 1.152-2.162) for tiotropium, 2.068l (95% CI: 1.385-2.752) for salmeterol, and 2.541l (95% CI: 1.954-3.129) for tiotropium + salmeterol. Only the difference between tiotropium and the tiotropium + satmeterol combination was statistically significant (P = 0.01). The FEV1 AUCs(0-24h) were 2.854l(95% CI: 1.928-3.780) for tiotropium, 2.786l(95% CI: 1.913-3.660) for salmeterol, and 3.640l (95% CI: 2.674-4.605) for tiotropium + salmeterol. All differences between treatments were not statistically significant (P > 0.05). These results seem to indicate that the use of the tiotropium + satmeterol combination is more efficacious than the single agents alone, but the once-daily administration of the two drugs is inadvisable due to the broncholytic profile of salmeterol. (C) 2004 Published by Elsevier Ltd.
引用
收藏
页码:1214 / 1221
页数:8
相关论文
共 24 条
[11]   The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD [J].
Dorinsky, PM ;
Reisner, C ;
Ferguson, GT ;
Menjoge, SS ;
Serby, CW ;
Witek, TJ .
CHEST, 1999, 115 (04) :966-971
[12]   Effects of salmeterol on muscarinic inhibition of adenylyl cyclase in bovine trachealis cells [J].
Ethier, MF ;
Dextradeur, T ;
Schaefer, OP ;
Madison, JM .
LIFE SCIENCES, 2000, 67 (22) :2753-2758
[13]   BRONCHODILATING EFFECTS OF COMBINED THERAPY WITH CLINICAL DOSAGES OF IPRATROPIUM BROMIDE AND SALBUTAMOL FOR STABLE COPD - COMPARISON WITH IPRATROPIUM BROMIDE ALONE [J].
IKEDA, A ;
NISHIMURA, K ;
KOYAMA, H ;
IZUMI, T .
CHEST, 1995, 107 (02) :401-405
[14]   USE OF NON-PARAMETRIC METHODS IN STATISTICAL-ANALYSIS OF 2-PERIOD CHANGE-OVER DESIGN [J].
KOCH, GG .
BIOMETRICS, 1972, 28 (02) :577-+
[15]   Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease [J].
Littner, MR ;
Ilowite, JS ;
Tashkin, DP ;
Friedman, M ;
Serby, CW ;
Menjoge, SS ;
Witek, TJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1136-1142
[16]  
Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
[17]  
Pearson MG, 1997, THORAX, V52, pS1
[18]   OPTIMAL ASSESSMENT AND MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE (COPD) [J].
SIAFAKAS, NM ;
VERMEIRE, P ;
PRIDE, NB ;
PAOLETTI, P ;
GIBSON, J ;
HOWARD, P ;
YERNAULT, JC ;
DECRAMER, M ;
HIGENBOTTAM, T ;
POSTMA, DS ;
REES, J .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (08) :1398-1420
[19]   EFFECT OF BA-679-BR, A NOVEL LONG-ACTING ANTICHOLINERGIC AGENT, ON CHOLINERGIC NEUROTRANSMISSION IN GUINEA-PIG AND HUMAN AIRWAYS [J].
TAKAHASHI, T ;
BELVISI, MG ;
PATEL, H ;
WARD, JK ;
TADJKARIMI, S ;
YACOUB, MH ;
BARNES, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (06) :1640-1645
[20]   The role of long-acting bronchodilators in the management of stable COPD [J].
Tashkin, DP ;
Cooper, CB .
CHEST, 2004, 125 (01) :249-259